Supplementary Methods, Figure Legends, and References from Context-Dependent Role of Angiopoietin-1 Inhibition in the Suppression of Angiogenesis and Tumor Growth: Implications for AMG 386, an Angiopoietin-1/2–Neutralizing Peptibody

Coxon, Angela; Bready, James; Min, Hosung; Kaufman, Stephen; Leal, Juan; Yu, Dongyin; Lee, Tani Ann; Sun, Ji-Rong; Estrada, Juan; Bolon, Brad; McCabe, James; Wang, Ling; Rex, Karen; Caenepeel, Sean; Hughes, Paul; Cordover, David; Kim, Haejin; Han, Seog Joon; Michaels, Mark L.; Hsu, Eric; Shimamoto, Grant; Cattley, Russell; Hurh, Eunju; Nguyen, Linh; Wang, Shao Xiong; Ndifor, Anthony; Hayward, Isaac J.; Falcón, Beverly L.; McDonald, Donald M.; Li, Luke; Boone, Tom; Kendall, Richard; Radinsky, Robert; Oliner, Jonathan D.

doi:10.1158/1535-7163.22486035.v1

mct_9_10_2641.pdf (109.38 kB)

Supplementary Methods, Figure Legends, and References from Context-Dependent Role of Angiopoietin-1 Inhibition in the Suppression of Angiogenesis and Tumor Growth: Implications for AMG 386, an Angiopoietin-1/2–Neutralizing Peptibody

journal contribution

posted on 2023-03-31, 23:31 authored by Angela Coxon, James Bready, Hosung Min, Stephen Kaufman, Juan Leal, Dongyin Yu, Tani Ann Lee, Ji-Rong Sun, Juan Estrada, Brad Bolon, James McCabe, Ling Wang, Karen Rex, Sean Caenepeel, Paul Hughes, David Cordover, Haejin Kim, Seog Joon Han, Mark L. Michaels, Eric Hsu, Grant Shimamoto, Russell Cattley, Eunju Hurh, Linh Nguyen, Shao Xiong Wang, Anthony Ndifor, Isaac J. Hayward, Beverly L. Falcón, Donald M. McDonald, Luke Li, Tom Boone, Richard Kendall, Robert Radinsky, Jonathan D. Oliner

Supplementary Methods, Figure Legends, and References from Context-Dependent Role of Angiopoietin-1 Inhibition in the Suppression of Angiogenesis and Tumor Growth: Implications for AMG 386, an Angiopoietin-1/2–Neutralizing Peptibody

History

ARTICLE ABSTRACT

AMG 386 is an investigational first-in-class peptide-Fc fusion protein (peptibody) that inhibits angiogenesis by preventing the interaction of angiopoietin-1 (Ang1) and Ang2 with their receptor, Tie2. Although the therapeutic value of blocking Ang2 has been shown in several models of tumorigenesis and angiogenesis, the potential benefit of Ang1 antagonism is less clear. To investigate the consequences of Ang1 neutralization, we have developed potent and selective peptibodies that inhibit the interaction between Ang1 and its receptor, Tie2. Although selective Ang1 antagonism has no independent effect in models of angiogenesis-associated diseases (cancer and diabetic retinopathy), it induces ovarian atrophy in normal juvenile rats and inhibits ovarian follicular angiogenesis in a hormone-induced ovulation model. Surprisingly, the activity of Ang1 inhibitors seems to be unmasked in some disease models when combined with Ang2 inhibitors, even in the context of concurrent vascular endothelial growth factor inhibition. Dual inhibition of Ang1 and Ang2 using AMG 386 or a combination of Ang1- and Ang2-selective peptibodies cooperatively suppresses tumor xenograft growth and ovarian follicular angiogenesis; however, Ang1 inhibition fails to augment the suppressive effect of Ang2 inhibition on tumor endothelial cell proliferation, corneal angiogenesis, and oxygen-induced retinal angiogenesis. In no case was Ang1 inhibition shown to (a) confer superior activity to Ang2 inhibition or dual Ang1/2 inhibition or (b) antagonize the efficacy of Ang2 inhibition. These results imply that Ang1 plays a context-dependent role in promoting postnatal angiogenesis and that dual Ang1/2 inhibition is superior to selective Ang2 inhibition for suppression of angiogenesis in some postnatal settings. Mol Cancer Ther; 9(10); 2641–51. ©2010 AACR.